Table 3.

 Subtype‐specific NI titers in human volunteers pre‐ and post‐immunization with seasonal trivalent influenza vaccines*

Vaccine group	Human volunteer	NI to N1NewCal/99		NI to N2Wis/05
		Pre	Post	Pre	Post
LAIV	#1	5	10	10	10
	#3	20	20	40	40
	#4	10	10	10	10
	#5	<5	<5	40	20
	#6	20	40	5	10
	#7	5	20	10	20
	#8	<5	5	5	20
	#9	5	5	<5	<5
	#10	10	10	<5	5
	#13	40	40	80	80
	#14	<5	5	5	5
	#17	10	10	10	5
	#18	80	80	10	20
	#19	10	10	<5	5
	#21	20	20	20	20
	#35	80	80	80	40
	GMT	10·9	14·1	10·9	13·0
	Response rate		31%		38%
TIV	#11	10	20	10	10
	#12	5	10	20	40
	#15	5	10	20	20
	#20	5	5	10	10
	#22	20	20	10	10
	#23	10	20	10	10
	#24	10	10	10	10
	#25	160	160	10	10
	#26	<5	<5	40	40
	#28	20	20	10	20
	#29	10	10	10	20
	#30	10	10	10	40
	#31	5	5	10	10
	#32	5	5	20	40
	#33	10	20	10	20
	#34	20	40	40	80
	GMT	10·0	13·0	13·5	19·2
	Response rate		38%		44%

LAIV, live‐attenuated influenza vaccine; TIV, trivalent inactivated vaccine; NI, neuraminidase inhibition; GMT, geometric mean titer.

*Sera assayed against H6N1_NewCal/99 and H6N2_Wis/05 antigens.